METABOLIC-ASSOCIATED  STEATOTIC LIVER DISEASE,  OBESITY, AND HYPOTHYROIDISM:  THE CLINICAL ROLE OF VITAMIN D

Kateryna Pivtorak; Oleksandr Ivanchuk; Nataliya Pivtorak; Tetyana Shevchuk

doi:10.36074/grail-of-science.15.05.2026.150

METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE, OBESITY, AND HYPOTHYROIDISM: THE CLINICAL ROLE OF VITAMIN D

Authors

Kateryna Pivtorak National Pirogov Memorial Medical University, Ukraine https://orcid.org/0000-0001-9187-7964
Oleksandr Ivanchuk National Pirogov Memorial Medical University, Ukraine https://orcid.org/0000-0002-3008-5207
Nataliya Pivtorak Vinnytsia Mykhailo Kotsiubynskyi State Pedagogical Universityy, Ukraine https://orcid.org/0000-0002-0162-3010
Tetyana Shevchuk Pirogov Vinnytsia Regional Clinical Hospital, Ukraine https://orcid.org/0000-0002-4802-8753

DOI:

https://doi.org/10.36074/grail-of-science.15.05.2026.150

Keywords:

MASLD, obesity, microbiota, hypothyroidism, vitamin D, insulin resistance, systemic inflammation.

Summary

The article reviews current understanding of the relationship between hypothyroidism and metabolic-associated steatotic liver disease (MASLD) and obesity. The main pathogenetic mechanisms are analyzed, including lipid and carbohydrate metabolism disorders, insulin resistance, and chronic inflammation. Particular attention is paid to the role of vitamin D as an important regulatory factor affecting metabolic processes, immune response, and liver fibrogenesis. The results of current studies on the impact of vitamin D deficiency on the course of metabolic disorders and the functional state of the liver are summarized. The prospects for the use of vitamin D as a potential component of complex therapy for these pathological conditions are considered.

Downloads

PDF

Downloads

Download data is not yet available.

License

References

Sbraccia P, Finer N, editors. Obesity. Pathogenesis, Diagnosis, and Treatment. Springer; 2019. Part of the Endocrinology book series (ENDOCR), Cordero P, Li J, Oben JA. Obesity and NAFLD; p. 179-194.

Pivtorak, K., Fedzhaga, I., Pivtorak, N., Vozniuk, L., & Klekot, O. (2022). Fat and muscle components of body weight and their relationship with the concentration of serum adipokines in patients with nonalcoholic fatty liver disease. Wiad Lek, 75(5 pt 2), 1289-1294. DOI: https://doi.org/10.36740/WLek202205210

Півторак КВ. Антропометричне дослідження хворих на неалкогольну жирову хворобу печінки. Запорожский медицинский журнал. 2017; 19, 5(104): 623-628.

Loomis KA, Kabadi S, Preiss D, Hyde C, Bonato V, St Louis M, et al. Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective Studies. J Clin Endocrinol Metab. 2016 Mar; 101(3): 945-952. doi: 10.1210/jc.2015-3444. DOI: https://doi.org/10.1210/jc.2015-3444

Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017 Jan; 14(1): 32-42. doi: 10.1038/nrgastro.2016.147. DOI: https://doi.org/10.1038/nrgastro.2016.147

Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology. 2016 Oct; 63(1): 138-147. doi: 10.1002/hep.27981. DOI: https://doi.org/10.1002/hep.27981

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul; 64: 73-84. DOI: https://doi.org/10.1002/hep.28431

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012 Sep; 56(3): 943-951. doi: 10.1002/hep.25772. DOI: https://doi.org/10.1002/hep.25772

Pivtorak, K. V., Shcherbeniuk, N. V., Pivtorak, N. A., Mazur, H. M., & Luchenko, Ya. V. (2025). The role of endothelial dysfunction and insulin resistance in the development of cardiovascular complications in patients with metabolic dysfunction-associated steatotic liver disease. Prospects and Innovations of Science, 2(48), 1917–1936. DOI: https://doi.org/10.52058/2786-4952-2025-2(48)-1917-1935

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015 Aug; 149(2): 389-397. e10. doi: 10.1053/j.gastro.2015.04.043. DOI: https://doi.org/10.1053/j.gastro.2015.04.043

Півторак КВ. Дисфункція ендотелію та порушення функції печінки при неалкогольній жировій хворобі печінки. Вісник Вінницького національного медичного університету 2015; 19(2), 540-544.

Степанов ЮМ, Филиппова АЮ. Дислипидемия у пациентов с неалкогольным стеатозом печени и билиарной патологией и пути ее коррекции. Сучасна гастроентерологія. 2010; 4(54): 46-51.

Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and Cardiovascular Damage in Patients with Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin. Gastroenterol. Hepatol. 2017 Oct; 15(10): 1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. DOI: https://doi.org/10.1016/j.cgh.2017.04.045

Пивторак ЕВ. Нарушения функции эндотелия у больных неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2014; 102(2): 63.

Enjoji, M.; Yasutake, K.; Kohjima, M.; Nakamuta, M. Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol. Int. J. Hepatol. 2012; 2012: 1-6. doi: 10.1155/2012/925807. DOI: https://doi.org/10.1155/2012/925807

Perdomo CM, Frühbeck G, Escalada J. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients. 2019 Mar 21; 11(3): pii: E677.

Safari F, Nabavizadeh A, Vardanjani HM. The association between thyroid function and insulin resistance as measured by the metabolic score for insulin resistance (METS-IR): insights from NHANES 2007-2012. BMC Endocr Disord. 2024;24(1):267. Published 2024 Dec 18. doi:10.1186/s12902-024-01779-y DOI: https://doi.org/10.1186/s12902-024-01779-y

Pivtorak, K. V., Ivanchuk, O. V., Pivtorak, N. A., Burkov, M. V., Pashinskyi, Y. M., & Shcherbeniuk, N. V. (2025). Role of vitamin D in cardiovascular complications of metabolic-associated steatotic liver disease. World of Medicine and Biology, 3(93), 235-241. DOI: https://doi.org/10.26724/2079-8334-2025-3-93-235-241

Півторак КВ. Особливості фармакотерапії неалкогольної жирової хвороби печінки у хворих з надлишковою масою тіла та ожирінням. Запорізький медичний журнал. 2017; 19, 4 (103): 520-524.

Pivtorak, K.V., Mazur, I.A., & Voloshin, M.A. (2017) Correction of metabolic disorders caused by non-alcoholic fatty liver disease. Deutscher wissenschaftsherold German Science Herald. 4: 74-77.

Ruiz, C.G. & Checa, J.C.F. (2018) Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease. Hepatol Commun. 2(12): 1425-1439. DOI: https://doi.org/10.1002/hep4.1271

Pivtorak KV, Shevchuk NA, Pivtorak NA, Fedzhaga IV. Correction of adipocyte secretion disorders in patients with non-alcoholic fatty liver disease with overweight and obesity. Wiad Lek. 2019 Aug 31;72(8):1477-1480. DOI: https://doi.org/10.36740/WLek201908111

Perdomo, C. M., Frühbeck, G., & Escalada, J. (2019). Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients, 11(3), 677. DOI: https://doi.org/10.3390/nu11030677

Pivtorak K, Yakovleva O, Pivtorak N, Fedzhaga I, Doroshkevich I. Metabolic features of adipose tissue and clinical significance of adipokins in patients with non-alcoholic fatty liver disease (review). Georgian Medical News 2021. 7-8 (316-317), 135-141.

Півторак, К.В., Марчук О.В. (2022). Неалкогольна жирова хвороба печінки та саркопенія. Вісник проблем біології і медицини. 3(166): 79-86.

Pivtorak K, Monastyrskyi V, Kuleshov O, Fedzhaga I, Pivtorak N. Relationship between sarcopenia and osteoporosis in non-alcoholic fatty liver disease. Georgian Med News. 2022 May;(326):12-17.

Півторак КВ. Особливості клітинного циклу гепатоцитів при експериментальній неалкогольній жировій хворобі печінки та її корекції. Вісник проблем біології і медицини.. 2017; 1 (135): 170-174.

Півторак К.В., Булько М.П., Півторак Н.А., Булько І.В. (2025). Метаболічно асоційована стеатотична хвороба печінки: значення ожиріння та запального процесу. Перспективи та інновації науки, 3(61), 2550-2559. DOI: https://doi.org/10.52058/2786-4952-2026-3(61)-2550-2559

Khosravi-Boroujeni H, Mowla K, Asadi Z, Omidian M, Rezaei S, Mirmiran P, et al. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trial. Nutr J. 2024;23:24. DOI: https://doi.org/10.1186/s12937-024-00911-x